Author of the article: Ian MacAlpine
Publishing date: Dec 23, 2020 • December 23, 2020 • 1 minute read
Article content
Kingston Health Sciences Centre said operations will remain the same as they have since the COVID-19 pandemic began in March, as Ontario prepares to enter a provincewide lockdown at midnight Wednesday.
“At this time, we have not received a provincial directive to reduce our non-emergency surgical activity and clinic work,” Dr. David Pichora, president and CEO of KHSC, wrote in a statement on Wednesday. “We will continue to monitor the situation daily, as we have been for the past many months, and adjust our activity as needed based on the prevalence of COVID-19 in our communities, supplies, bed capacity and staffing.”
Hits: 889
TSHA-101 to be first bicistronic vector evaluated in human clinical trials; TSHA-101 designed to deliver both HEXA and HEXB transgenes within a single AAV9 vector construct
TSHA-101 CTA is the second clinical trial clearance received, in addition to TSHA-118’s open investigational new drug application for CLN1
Interim data from Phase 1/2 trial anticipated in 2021
DALLAS, TX, USA I December 21, 2020 I Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that Queen’s University in Ontario, Canada, received Clinical Trial Application (CTA) approval from Health Canada for its investigator-sponsored Phase 1/2 trial exploring TSHA-101, Taysha’s investigational AAV9-based gene therapy, for the treatment of infantile GM2 gangliosidosis.
Taysha Gene Therapies Announces Queen s University s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Article content
Outpatients who answer “yes” to the questions will be “managed with extra precautions,” and inpatients who answer “yes” will be placed under quarantine for eight days.
The extra screening questions come as COVID-19 prevalence continues to rise both across the region and the province, the release said. The entrance to a COVID-19 assessment clinic at Hotel Dieu Hospital in Kingston. Photo by Handout photo
“(Kingston Health Sciences Centre) requires patients and visitors alike to answer these questions due to the continued increase of community spread of COVID-19 throughout the Kingston area and additional regions across Ontario entering red and grey status,” Dr. Gerald Evans, the organization’s medical director of infection control, said in a written statement.
Article content
Outpatients who answer “yes” to the questions will be “managed with extra precautions,” and inpatients who answer “yes” will be placed under quarantine for eight days.
The extra screening questions come as COVID-19 prevalence continues to rise both across the region and the province, the release said. The entrance to a COVID-19 assessment clinic at Hotel Dieu Hospital in Kingston. Photo by Handout photo
“(Kingston Health Sciences Centre) requires patients and visitors alike to answer these questions due to the continued increase of community spread of COVID-19 throughout the Kingston area and additional regions across Ontario entering red and grey status,” Dr. Gerald Evans, the organization’s medical director of infection control, said in a written statement.